Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
3,640.00    0.00 (0.00%)
Bid:
3,654.00
Ask:
3,658.00
Spread: 4.00 (0.109%)
Market Cap: £13.75b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisition

27 Apr 2021 07:00

RNS Number : 6459W
Halma PLC
27 April 2021
 

Halma plc ('Halma' or the 'Group')

Acquisition

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today announces that it has acquired PeriGen, Inc., ("PeriGen"), based in North Carolina, USA.

PeriGen's advanced technology protects mothers and their unborn babies by alerting doctors, midwives and nurses to potential problems during childbirth. Its software solutions use artificial intelligence to provide an automated early warning platform during labour, enabling healthcare professionals to assess complex data more easily and allowing them to spend more time on direct patient care.

The cash consideration for PeriGen is US$58m (approximately £42m), on a cash and debt free basis, which will be funded from Halma's existing facilities. PeriGen's unaudited revenue for the 12 months to the end of March 2021 was approximately US$20m (approximately £14m), with return on sales slightly above Halma's target range of 18%-22%.

Andrew Williams, Group Chief Executive at Halma, commented:

"We are excited by the opportunities offered by PeriGen's digital technology in helping clinicians protect the health of mothers and babies during childbirth, while achieving better clinical outcomes in the increasing proportion of complex births. PeriGen is highly aligned with our purpose, broadens our presence in patient assessment and monitoring into the US perinatal care market, and further extends our artificial intelligence and analytics capabilities."

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Andrew Jaques / Giles Robinson +44 (0)20 3128 8788

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

 

 

 

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2021, Halma was named Britain's Most Admired Company by Management Today.

Further information on PeriGen

PeriGen's Electronic Fetal Monitoring (EFM) software is used in childbirth to continuously assess fetal heart rate and contraction patterns, maternal vital signs, and labour progress at both the bedside and from central nursing stations. It provides clinical warning signs during labour, including trending alerts to notify clinicians of situations that may require interventions.

PeriGen's Vigilance early warning system is the only FDA cleared, automated and continuous assessment tool for trending maternal and fetal clinical warning signs in childbirth. This analytics solution is powered by an AI machine-learning algorithm that guides doctors and nurses during childbirth.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQIFMPTMTBTBBB
Date   Source Headline
5th Mar 20209:00 amRNSInvestor Event
24th Feb 202011:31 amRNSHolding(s) in Company
21st Feb 20207:00 amRNSAcquisition
5th Feb 20207:00 amRNSAcquisition
27th Jan 20207:00 amRNSAcquisition
22nd Jan 202012:58 pmRNSChange of Remuneration Committee Chair
29th Nov 20191:27 pmRNSDirector/PDMR Shareholding
25th Nov 20195:10 pmRNSDirector/PDMR Shareholding
19th Nov 201911:45 amRNSDividend Declaration
19th Nov 20197:00 amRNSHalf-year Report
2nd Oct 20195:02 pmRNSDirector/PDMR Shareholding
1st Oct 20197:00 amRNSSite Visit
25th Sep 20197:00 amRNSTrading Statement
29th Jul 20199:44 amRNSDirector/PDMR Shareholding
25th Jul 20196:27 pmRNSResult of AGM
25th Jul 20197:00 amRNSNotice of Board Change
15th Jul 201911:01 amRNSHolding(s) in Company
15th Jul 201910:38 amRNSCompletion of Acquisition
4th Jul 20192:09 pmRNSDirector/PDMR Shareholding
2nd Jul 20194:47 pmRNSDirector/PDMR Shareholding
2nd Jul 201910:34 amRNSHolding(s) in Company
21st Jun 201910:52 amRNSAnnual Financial Report
21st Jun 20197:00 amRNSAcquisition
11th Jun 20197:00 amRNSFinal Results
29th May 20194:00 pmRNSHolding(s) in Company
28th May 201912:59 pmRNSHolding(s) in Company
23rd May 201910:46 amRNSHolding(s) in Company
22nd May 20191:49 pmRNSHolding(s) in Company
21st May 20196:28 pmRNSHolding(s) in Company
17th May 20195:08 pmRNSHolding(s) in Company
13th May 201910:37 amRNSHolding(s) in Company
30th Apr 20199:33 amRNSHolding(s) in Company
17th Apr 201910:13 amRNSHolding(s) in Company
22nd Mar 20199:34 amRNSHolding(s) in Company
21st Mar 201912:30 pmRNSHolding(s) in Company
21st Mar 20197:00 amRNSTrading Statement
7th Feb 20192:00 pmRNSInvestor Event
18th Jan 20197:00 amRNSAcquisition
18th Dec 201811:02 amRNSDirector Declaration
20th Nov 20183:21 pmRNSDoc re. Half Year Report
20th Nov 20187:00 amRNSHalf-year Report
16th Nov 20187:00 amRNSAcquisition
19th Oct 20187:00 amRNSAcquisition
2nd Oct 20184:39 pmRNSDirector/PDMR Shareholding
27th Sep 20187:00 amRNSTrading Statement
2nd Aug 20183:29 pmRNSDirector/PDMR Shareholding
1st Aug 20185:23 pmRNSTotal Voting Rights
27th Jul 201810:39 amRNSDirector/PDMR Shareholding
19th Jul 20184:45 pmRNSResult of AGM
4th Jul 201810:25 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.